Drug Trial Radar · NCT02255435
A Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in People Aged 16 to 40 With Friedreich's Ataxia
Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
172
Actual
Start
Jan 31, 2015
Primary completion
Oct 31, 2019
Study completion Dec 19, 2025
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- Collaborators
- AbbVie; Friedreich's Ataxia Research Alliance
- First posted
- Oct 2, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years, up to 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this study, researchers are learning more about RTA 408, also known as omaveloxolone, BIIB141, or SKYCLARYS®. The main goal of this study is to learn more about the safety of RTA 408 and how it affects physical effort, movement, coordination, and how participants feel in daily life. The main questions researchers want to answer in this study are: * How much physical effort can a participant produce during a cycling test after 12 weeks of treatment? * How do scores on the modified Friedreich's Ataxia Rating Scale (mFARS) change after 48 weeks? Researchers will use the modified Friedreich's Ataxia Rating Scale (mFARS) to measure how FA affects the nervous system. The mFARS looks at movement ability, balance, coordination, speech, and how well the arms and legs work. They will also use a cycling test to measure physical effort, along with questionnaires to learn how participants feel and function in daily life. Safety will also be tested using physical exams, vital sign checks, echocardiograms (ECHO), electrocardiograms (ECG), and blood and urine tests. The study will be done in 2 main parts, followed by an optional Extension period: * In Part 1, participants will be randomly assigned to take different doses of RTA 408 or a placebo by mouth once a day for 12 weeks. A placebo looks like the study drug but contains no real medicine. * Researchers will compare these doses to decide which one to use in Part 2. * In Part 2, a different group of participants will take either the chosen dose of RTA 408 (150 mg) or placebo once a day for 48 weeks. * Participants who complete Part 1 or Part 2 may be able to join an Extension period, where everyone receives RTA 408. * In the Extension period, participants will continue to receive RTA 408 until the drug becomes commercially available or until they leave the study * Participants in Part 1 will have up to 9 study visits and 2 phone calls. If they do not move onto the Extension period, they will stay in the study for up to 20 weeks. * Participants in Part 2 will have up to 10 study visits and 3 phone calls. If they do not move onto the Extension period, they will stay in the study for up to 61 weeks. * Participants in the Extension period will have 2 visits in the first month, followed by visits every 6 months.
Conditions
- Friedreich Ataxia
Interventions
Omaveloxolone Capsules, 2.5 mgDrug
Omaveloxolone Capsules, 5 mgDrug
Omaveloxolone Capsules, 10 mgDrug
PlaceboDrug
Omaveloxolone Capsules, 20 mgDrug
Omaveloxolone Capsules, 40 mgDrug
Omaveloxolone Capsules, 80 mgDrug
Omaveloxolone Capsules, 160 mgDrug
Omaveloxolone Capsules, 300 mgDrug
Omaveloxolone Capsules, 150 mgDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Change From Baseline in Peak Work During Maximal Exercise Testing at Week 12Time frame: Baseline, Week 12
- Part 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)Time frame: From first dose of study drug up to end of Part 1 of the study (up to Week 16)
- Part 2: Change From Baseline in the Modified Friedreich's Ataxia Rating Scale (mFARS) at Week 48Time frame: Baseline, Week 48
- Part 2: Number of Participants With TEAEs and TESAEsTime frame: From first dose of study drug up to end of Part 2 of the study (up to Week 52)
Locations
11 sites in 5 countries. Site status is shown where the registry gives one.
UCLA
Los Angeles, California
University of Florida - Neurology
Gainesville, Florida
USF Ataxia Research Center
Tampa, Florida
Emory University Hospital - Neurology
Atlanta, Georgia
University of Iowa Stead Family Children's Hospital
Iowa City, Iowa
Ohio State University - Neurology
Columbus, Ohio
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Murdoch Childrens Research Institute
Parkville, Victoria, Australia
Medical University Innsbruck
Innsbruck, Austria
Neurological Institute Carlo Besta
Milan, Italy
University College of London
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.